We hypothesize that targeting SIRT7 might be beneficial for treating EGF signaling-dependent cancers, e.g., triple-negative breast cancers with increased EGFR expression and activity, colorectal and pancreatic cancers that harbor Ras mutations and NSCLCs with EGFR mutations. Here, EGF is linked to pancreatic neoplasm.